A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 30 Jan 2017 Planned number of patients changed from 100 to 30.
- 30 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2020.
- 30 Jan 2017 Status changed from recruiting to active, no longer recruiting.